Attentive motion tracking deficits measured using multiple object tracking (MOT) tasks have been identified in a number of neurodevelopmental disorders such as amblyopia and autism. These deficits are often attributed to the abnormal development of high-level attentional networks. However, neuroimaging evidence from amblyopia suggests that reduced MOT performance can be explained by impaired function in motion-sensitive area MT+ alone. To test the hypothesis that a subtle disruption of MT+ function could cause MOT impairment, we assessed whether continuous theta burst stimulation (cTBS) of MT+ influenced MOT task accuracy in individuals with normal vision. The MOT stimulus consisted of four target and four distractor dots and was presented at AE10 eccentricity (right/left hemifield). fMRI-guided cTBS was applied to left MT+. Participants (n = 13, age: 27 AE 3) attended separate active and sham cTBS sessions where the MOT task was completed before, 5-min post-and 30-min post-cTBS. Active cTBS significantly impaired MOT task accuracy relative to baseline for the right (stimulated) hemifield 5-min (10 AE 2% reduction) and 30-min (14 AE 3% reduction) post-stimulation. No impairment occurred within the left (control) hemifield after active cTBS or for either hemifield after sham cTBS. These results highlight the importance of lower level motion processing for MOT, suggesting that a minor disruption of MT+ function alone is sufficient to cause a deficit in MOT performance.

This proceeding examines the unique aspects of wearable sensor technology in the domain of bipolar disorder. Specifically, the proceeding examines the current literature on the use cases, design, data analysis models, and ethics to identify the design implications for the future design of wearable technology for people diagnosed with bipolar disorder and, potentially, other affective disorders. As a result, suggestions have been proposed to enhance the human– computer interaction between the user and device, a critical aspect in design as defined by the patients.

Background: More than 86,000 Americans with type 2 diabetes mellitus (T2DM) undergo nontraumatic lower-extremity amputations annually. The opioid-prescribing practice of podiatric surgeons remains understudied. We hypothesized that patients with T2DM who undergo any forefoot amputation while using antidepressant medication will have reduced odds of using opioids beyond 7 days. Methods: We completed a retrospective cohort study examining patients with T2DM who underwent forefoot amputation (toe, ray, transmetatarsal). Data were restricted to patients with a hemoglobin A1c level less than 8.0% and an ankle-brachial index greater than 0.8. The outcome was use of postoperative opioids beyond 7 days. Patients received an initial opioid prescription of 7 days or less. We developed simple logistic regression models to identify the odds of a patient using opioids beyond 7 days by patient variables: age, race, sex, amputation level, body mass index, antidepressant medication use, and marital status. Variables with P < .1 in the univariate analysis were included in the multiple logistic regression model. Results: Fifty patients met the inclusion criteria. Antidepressant use and marital status were the only statistically significant variables. Adjusting for marital status, patients with antidepressant use had decreased odds (odds ratio, 0.018; 95% confidence interval, 0.001–0.229; P = .002) of using opioids beyond 7 days after a diabetic forefoot amputation. Conclusions: Patients with T2DM who used antidepressants had significantly reduced odds of using opioids beyond 1 week after forefoot amputations compared with those without antidepressant use. We proposed an underlying diabetic foot–pain–depression cycle. To break the cycle, podiatric surgeons should screen this population for depression preoperatively and postoperatively and not hesitate to make a mental health referral if warranted. Nontraumatic amputations can be a traumatic experience for patients; psychiatrists and other mental health providers should be members of limb preservation teams.

No abstract

Attentive motion tracking deficits, measured using multiple object tracking (MOT) tasks, have been identified in a number of visual and neurodevelopmental disorders such as amblyopia and autism. These deficits are often attributed to the abnormal development of high-level attentional networks. However, neuroimaging evidence from amblyopia suggests that reduced MOT performance can be explained by impaired function in motion sensitive area MT+ alone. To test the hypothesis that MT+ plays an important role in MOT, we assessed whether modulation of MT+ activity using continuous theta burst stimulation (cTBS) influenced MOT performance in participants with normal vision. An additional experiment involving numerosity judgements of MOT stimulus elements was conducted to control for non-specific effects of MT+ cTBS on psychophysical task performance. The MOT stimulus consisted of 4 target and 4 distractor dots and was presented at 10° eccentricity in the right or left hemifield. Functional MRI-guided cTBS was applied to left MT+. Participants (n = 13, age:27 ± 3) attended separate active and sham cTBS sessions where the MOT task was completed before, 5 mins post and 30 mins post cTBS. Active cTBS significantly impaired MOT task accuracy relative to baseline for the right (stimulated) hemifield 5 mins (10 ± 2% reduction; t12 = 1.95, p = 0.03) and 30 mins (14 ± 3% reduction; t12 = 2.96, p = 0.01) post stimulation. No impairment occurred within the left (control) hemifield after active cTBS or for either hemifield after sham cTBS. Numerosity task performance was unaffected by cTBS. These results highlight the importance of lower-level motion processing for MOT and suggest that abnormal function of MT+ alone is sufficient to cause a deficit in MOT task performance.